World's Best Scientists 2026 revealed!
Award Badge
Best Scientists
2025
Award Badge
Best Female Scientists
2025

D-Index & Metrics

Best Female Scientists

D-Index
188
Citations
139276
World Ranking
31
National Ranking
22

Best Scientists

D-Index
188
Citations
139276
World Ranking
455
National Ranking
299

Medicine

D-Index
189
Citations
143035
World Ranking
265
National Ranking
177

Research.com Recognitions

  • 2025 - Research.com Best Female Scientists Award
  • 2025 - Research.com Best Scientists Award

Overview

Susan O'Brien is affiliated with the University of California, Irvine in the United States. Their research primarily spans the field of Medicine with a strong focus on Hematology, Public Health, Environmental and Occupational Health, Genetics, Pathology and Forensic Medicine, and Oncology as subfields.

Their major research topics include:

  • Acute Lymphoblastic Leukemia research
  • Chronic Lymphocytic Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Lymphoma Diagnosis and Treatment
  • CAR-T cell therapy research
  • Acute Myeloid Leukemia Research
  • Childhood Cancer Survivors' Quality of Life

Susan O'Brien's recent papers highlight investigational therapies and treatment outcomes in leukemia and lymphoma. These include:

  • Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results (2023, American Journal of Hematology)
  • A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL (2022, Blood Advances)
  • Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia (2020, Cancer)
  • Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial (2020, The Lancet Haematology)
  • Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience (2021, Blood Advances)

Frequent collaborators include:

  • Hagop M. Kantarjian
  • Elias Jabbour
  • Tapan M. Kadia
  • Nitin Jain
  • Guillermo Garcia-Manero

Their published work appears predominantly in the following venues:

  • Blood (15 publications)
  • Cancer (5 publications)
  • Clinical Lymphoma Myeloma & Leukemia (5 publications)
  • Blood Advances (2 publications)
  • Leukemia & lymphoma/Leukemia and lymphoma (2 publications)

The scope of Susan O'Brien's research is oriented towards understanding and developing treatments for various leukemias and lymphomas, gathering insights from clinical trials and long-term follow-up studies. The areas of interest also emphasize hematologic malignancy diagnosis, therapeutic intervention, and patient outcomes.

Best Publications

  • National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment

    Bruce D. Cheson;John M. Bennett;Michael Grever;Neil Kay

  • Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Ian W. Flinn

  • Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

    Moshe Talpaz;Neil P. Shah;Hagop M Kantarjian;Nicholas Donato

  • Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

    Richard R. Furman;Jeff P. Sharman;Steven E. Coutre;Bruce D. Cheson

  • Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

    J. C. Byrd;J. R. Brown;Susan O'Brien;J. C. Barrientos

  • The biology of chronic myeloid leukemia

    Stefan Faderl;Moshe Talpaz;Zeev Estrov;Susan O'Brien

  • iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

    Michael Hallek;Bruce D. Cheson;Daniel Catovsky;Federico Caligaris-Cappio

  • Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

    Hagop M Kantarjian;Francis Giles;Lydia Wunderle;Kapil Bhalla

  • Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy

    Sergio Giralt;Elihu Estey;Maher Albitar;Koen Van Besien

  • Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.

    I F Khouri;M Keating;M Körbling;D Przepiorka

  • Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia

    Michael J. Keating;Susan O'Brien;Maher Albitar;Susan Lerner

  • Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

    Max S. Topp;Nicola Gökbuget;Anthony S. Stein;Gerhard Zugmaier

  • Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

    Hagop M. Kantarjian;Daniel J. DeAngelo;Matthias Stelljes;Giovanni Martinelli

  • Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

    John C. Byrd;Bonnie Harrington;Susan O'Brien;Jeffrey A. Jones

  • Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes

    Alvaro Aguayo;Hagop M Kantarjian;Taghi Manshouri;Cristi Gidel

  • Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

    Hagop Kantarjian;Yasuhiro Oki;Guillermo Garcia-Manero;Xuelin Huang

  • Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia

    Hagop M Kantarjian;Susan O'Brien;Terry L. Smith;Jorge E Cortes

  • Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

    Constantine S. Tam;Susan O'Brien;William Wierda;Hagop Kantarjian

  • Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Jan A. Burger

  • Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

    Hagop Kantarjian;Deborah Thomas;Susan O'Brien;Jorge Cortes

Frequent Co-Authors

Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Jorge E. Cortes
Jorge E. Cortes Augusta University
William G. Wierda
William G. Wierda The University of Texas MD Anderson Cancer Center
Farhad Ravandi
Farhad Ravandi The University of Texas MD Anderson Cancer Center
Guillermo Garcia-Manero
Guillermo Garcia-Manero The University of Texas MD Anderson Cancer Center
Michael J. Keating
Michael J. Keating The University of Texas MD Anderson Cancer Center
Elias Jabbour
Elias Jabbour The University of Texas MD Anderson Cancer Center
Stefan Faderl
Stefan Faderl The University of Texas MD Anderson Cancer Center
Deborah A. Thomas
Deborah A. Thomas The University of Texas MD Anderson Cancer Center
Alessandra Ferrajoli
Alessandra Ferrajoli The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Medicine in the USA opens the door to a variety of healthcare careers, many of which can also be accessed and enhanced through online education. There is a growing demand for professionals in allied health fields, with flexible online degrees paving new pathways for students and working professionals alike.

Those interested in pharmacy careers can explore pharmacy degree online programs, which provide a convenient and often more affordable route to advanced pharmaceutical training. For students drawn to digital health records and data analysis, health informatics degrees are increasingly accessible and valuable in today’s tech-driven healthcare landscape.

Alternatively, those seeking entry-level positions or wishing to upskill quickly may consider a low cost medical coding and billing online program, which prepares graduates for administrative and technical roles in healthcare facilities. Nursing continues to be in high demand, and aspiring nurse practitioners can benefit from the cheapest nurse practitioner programs available online, which combine flexibility with career advancement potential.

Best Scientists Citing Susan O'Brien

Trending Scientists